{"entity":{"id":"nct07314723","kind":"trial","name":"9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer","aka":[],"tldr":"A phase 2 trial of Toripalimab in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.","summary":"9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer is a phase 2 interventional study registered as NCT07314723 by Mabwell (Shanghai) Bioscience Co., Ltd., with 90 participants planned, started 2025-08-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: 9MW2821 and Toripalimab Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07314723","url":"https://clinicaltrials.gov/study/NCT07314723"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["toripalimab"],"companies":["mabwell-shanghai-bioscience"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07314723","phase":"2","setting":"A Single Arm, Open-label, Multicenter, Phase II Clinical Study to Evaluate the Safety and Efficacy of 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","participation":[{"nct":"NCT07314723","source":"https://clinicaltrials.gov/study/NCT07314723","fetchedAt":"2026-10-07T16:55:39.854Z","studySha256":"a8ea7535e1774e2a3530b0ae7d3846231bcd927fca032462962fbd25ed5d18f6","overallStatus":"RECRUITING","lastUpdatePosted":"2026-01-02","leadSponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":90,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2025-08-01","startedType":"actual","enrolled":90,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07314723/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"company":[{"id":"mabwell-shanghai-bioscience","kind":"company","name":"Mabwell (Shanghai) Bioscience","route":"/companies/mabwell-shanghai-bioscience/"}]}}